A5009759474- Phagocytosis and Immune Regulation
- Prostate Cancer Treatment and Research
- Cancer, Hypoxia, and Metabolism
- Cancer Cells and Metastasis
- Angiogenesis and VEGF in Cancer
- Phytoestrogen effects and research
- Developmental Biology and Gene Regulation
- Cardiovascular Disease and Adiposity
- Immune cells in cancer
- Cancer Mechanisms and Therapy
- Wnt/β-catenin signaling in development and cancer
- Prostate Cancer Diagnosis and Treatment
- Cancer-related gene regulation
- Ubiquitin and proteasome pathways
- Cancer Immunotherapy and Biomarkers
- Cancer-related Molecular Pathways
- Cytokine Signaling Pathways and Interactions
- Microtubule and mitosis dynamics
- Hepatocellular Carcinoma Treatment and Prognosis
- Digestive system and related health
- Nanoplatforms for cancer theranostics
- Pancreatic and Hepatic Oncology Research
- Enzyme function and inhibition
- Body Image and Dysmorphia Studies
- NF-κB Signaling Pathways
Exelixis (United States)
2021-2022
Newark Beth Israel Medical Center
2019
Omniox (United States)
2016-2018
Saint Peter's University Hospital
2011
In-Q-Tel
2008
University of British Columbia
2000-2005
BC Cancer Agency
2002-2005
Zero to Three
2002
Aberrant expression of Jagged1 and Notch1 are associated with poor outcome in breast cancer. However, the reason that and/or Notch overexpression portends a prognosis is unknown. We identify Slug, transcriptional repressor, as novel target show elevated levels Slug correlate increased various human cancers. was essential for Notch-mediated repression E-cadherin, which resulted β-catenin activation resistance to anoikis. Inhibition ligand-induced signaling xenografted...
Androgen deprivation is currently a standard-of-care, first-line therapy for prostate cancer in the United States. Although this regimen effectively regresses androgen-dependent disease, relapse often occurs an androgen-independent manner and associated with poor prognosis. Such castration-resistant represents major clinical challenge, mechanisms underlying castration resistance are not fully understood. Epithelial-mesenchymal transition (EMT) key developmental process has also been...
Notch4 is a member of the Notch family transmembrane receptors that expressed primarily on endothelial cells. Activation in various cell systems has been shown to regulate fate decisions. The sprouting cells from microvessels, or angiogenesis, involves modulation phenotype. Based function other members and expression pattern Notch4, we postulated activation would modulate angiogenesis. Using an vitro endothelial-sprouting assay, show constitutively active human dermal microvascular (HMEC-1)...
Abstract Angiogenesis is a crucial event in the survival and progression of solid tumors. To determine whether angiogenesis acute myeloid leukemia (AML) an intrinsic property leukemic cells, vascularity bone marrow biopsies was determined. Bone newly diagnosed or post‐chemotherapy AML patients increased 4‐fold ( P < 0.01) 8.7‐fold 0.01), respectively, relative to controls. Vascular endothelial growth factor (VEGF) expression by blast cells assessed immunohistochemistry, cell supernatants...
The multi-receptor tyrosine kinase inhibitor XL092 has been developed to inhibit the activity of oncogenic targets, including MET, VEGFR2, and TAM family kinases TYRO3, AXL MER. Presented here is a preclinical evaluation XL092. causes significant decrease in tumor MET phosphorylation (P < 0.01) murine Hs 746T xenograft models relative vehicle, 96% inhibition VEGFR2 lungs. Dose-dependent growth with was observed various models, dose-dependent regression seen NCI-H441 model. Tumor enhanced...
ABSTRACT Hepatocellular carcinoma is the fifth most common cancer worldwide. Advanced hepatocellular with tumor thrombus metastasis to right atrium rare, generally considered inoperable, and has a poor prognosis. This article describes management of two patients incidental findings invasion into atrium.
Abstract Background: Cabozantinib, an inhibitor of MET, VEGFR2, AXL, and MER, has shown significant clinical activity in multiple solid tumors, both alone combination with immune checkpoint inhibitors (ICIs). XL092 a similar target profile to cabozantinib but significantly shorter half-life pharmacokinetic properties suitable for once daily oral dosing (Hsu, Eur J Cancer, 2020). In preclinical studies, the anti–PD-1 exhibited greater anti-tumor than either agent alone. Here, we describe...
Abstract A hypoxic microenvironment is a hallmark of cancer that has been shown in numerous types to drive tumor progression and poor patient outcomes. Hypoxia promotes evasion the host immune responses by generating an immunosuppressive through activation multiple pathways mediated predominantly, but not exclusively, hypoxia inducible factor-1 (HIF-1) signaling. We have previously Omniox' lead anti-cancer immunotherapeutic, OMX, well tolerated small large animals, efficiently accumulates...
Hypoxia, or lack of oxygen, is a hallmark glioblastoma and correlated with tumor progression decreased overall survival. As key modulator the microenvironment, hypoxia promotes immunosuppression through activation multiple signaling pathways such as hypoxia-inducible factor/HIF signaling. OMX an oxygen carrier biotherapeutic previously shown to: a) be well tolerated in small large animals, b) efficiently accumulate spontaneous canine brain tumors rodent orthotopic (GL261 F98), c)...